Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

Trial Profile

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

Phase of Trial: Phase II

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 13 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 08 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 1 Feb 2018.
    • 15 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top